8
am -
7
pm ET,
Monday
-
Friday
Phone
1-833-256-2748

We're Here for You

Benefit
Understanding Benefits

Your Case Manager will review your insurance coverage and answer any questions about your insurance benefits for ONPATTROTM (patisiran).

Benefits
Disease Education

Education can help you make more informed choices about your health. Your Case Manager can connect you with a Patient Education Liaison (PEL) who can answer questions about hereditary ATTR (hATTR) amyloidosis and provide valuable resources to help you and your family learn more about the condition.

Financial
Financial Assistance

Alnylam provides assistance options for qualifying individuals. Your Case Manager will work with you to determine eligibility.*

- Quick Start Program

- Patient Assistance Program (PAP)

- Commercial Copay Program

*Individuals must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Get more information about Alnylam and ONPATTRO by downloading the brochures below.

Alylam Separator Triangles

Your Questions Answered

We know that you may have a lot of questions about your treatment with ONPATTRO, no matter where you are on your journey. That's why we've provided answers to common questions we've received from others like you.

View the FAQs >

Discover More

Your Team

Meet the people at Alnylam Assist
who are ready to help you.

Meet the Team

Additional Resources

Learn more about
advocacy organizations.

Connect With Others

Bottom CTA
Phone

Call Laura:

1-833-256-2748

Monday - Friday, 8am - 7pm (ET)

We’ll help you work with your healthcare professional to begin the process

How to Get Started

Important Safety Information

What are the most important things I should know about ONPATTROTM (patisiran)?

ONPATTRO can cause:

• Infusion-related reactions

ONPATTRO is given as a drip into a vein (called an “intravenous infusion”). Reactions to this infusion may happen during treatment with ONPATTRO. Before each infusion you will be given medicines that help to lower the chance of infusion-related reactions.

Tell your doctor or nurse right away if you experience any of the following signs of an infusion-related reaction during treatment:

• Reddening of the face or body (flushing), skin warm
• Body aches or pain, including pain in the back, neck, or joints
• Feeling sick (nausea)
• Stomach pain
• Feeling short of breath, cough, or other breathing problems
• Headache
• Chest discomfort or chest pain
• Rash
• Chills
• Dizziness
• Feeling tired (fatigue)
• Rapid heart rate
• Facial swelling

 

If you have an infusion-related reaction, your doctor or nurse may slow down or stop your infusion, and you may need to take other medicines. When these reactions stop, or get better, your doctor or nurse may decide to start the infusion again.

• Low Vitamin A levels

Treatment with ONPATTRO lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking ONPATTRO, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of ONPATTRO?

The most common side effects of ONPATTRO are respiratory infections, such as colds, sinus infections, and nasal congestion, and infusion-related reactions. These are not all the possible side effects of ONPATTRO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is ONPATTRO?

ONPATTRO is a medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). ONPATTRO is used in adults only.

For additional information about ONPATTRO, please see the full Prescribing Information.